361 Capital LLC lifted its holdings in shares of Haemonetics Co. (NYSE:HAE) by 35.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,393 shares of the medical instruments supplier’s stock after purchasing an additional 6,354 shares during the quarter. 361 Capital LLC’s holdings in Haemonetics were worth $2,441,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of HAE. American Century Companies Inc. grew its holdings in shares of Haemonetics by 231.1% during the third quarter. American Century Companies Inc. now owns 1,005,784 shares of the medical instruments supplier’s stock worth $115,243,000 after purchasing an additional 701,976 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Haemonetics in the third quarter worth approximately $52,658,000. Carillon Tower Advisers Inc. purchased a new stake in Haemonetics in the third quarter worth approximately $48,597,000. HealthCor Management L.P. purchased a new stake in Haemonetics in the third quarter worth approximately $34,287,000. Finally, Renaissance Technologies LLC boosted its stake in Haemonetics by 14.6% in the third quarter. Renaissance Technologies LLC now owns 2,256,500 shares of the medical instruments supplier’s stock worth $258,550,000 after buying an additional 286,800 shares in the last quarter. 98.46% of the stock is owned by institutional investors.
Shares of Haemonetics stock opened at $88.62 on Friday. The company has a quick ratio of 1.64, a current ratio of 2.44 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.48 billion, a P/E ratio of 47.39, a price-to-earnings-growth ratio of 2.80 and a beta of 0.89. Haemonetics Co. has a 52 week low of $68.91 and a 52 week high of $117.56.
Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $247.36 million during the quarter, compared to the consensus estimate of $250.12 million. Haemonetics had a return on equity of 17.05% and a net margin of 4.84%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 earnings per share. On average, equities analysts predict that Haemonetics Co. will post 2.33 earnings per share for the current fiscal year.
Several analysts have weighed in on the company. Barrington Research boosted their price objective on Haemonetics to $112.00 and gave the company a “positive” rating in a research report on Wednesday, February 6th. ValuEngine downgraded Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research upgraded Haemonetics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 30th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $119.75.
In other Haemonetics news, SVP Jacqueline Scanlan sold 1,027 shares of the stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $104.22, for a total value of $107,033.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronald G. Gelbman sold 8,196 shares of the stock in a transaction on Friday, February 15th. The stock was sold at an average price of $86.52, for a total value of $709,117.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 19,112 shares of company stock valued at $1,833,419. 1.04% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This piece was posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://macondaily.com/2019/02/22/haemonetics-co-hae-holdings-lifted-by-361-capital-llc.html.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.